PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Ceftobiprole Medocaril→

Ceftobiprole Medocaril PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
376653-43-9
Molecular formula
C26H26N8O11S2
Molecular weight
690.7 g/mol
Drug class
Fifth-generation cephalosporin prodrugbroad-spectrum beta-lactam antibacterial
Mechanism of action
Ceftobiprole medocaril is converted to active ceftobiprole, which binds penicillin-binding proteins, including PBP2a in MRSA, and inhibits bacterial cell-wall synthesis.
Indications / reported uses
  • Treatment of Staphylococcus aureus bloodstream infection (bacteraemia), including right-sided infective endocarditis, caused by methicillin-susceptible or methicillin-resistant isolates in adults
  • Treatment of acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia in eligible patients under the product-specific label; route and age eligibility vary by indication

Sources: US DailyMed — ZEVTERA (ceftobiprole medocaril) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Ceftobiprole Medocaril PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Ceftobiprole Medocaril Permitted Daily Exposure (PDE) report (the Ceftobiprole Medocaril PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Ceftobiprole Medocaril Occupational Exposure Limit (OEL) report (the Ceftobiprole Medocaril OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.